CDK4 and metastatic neoplasm: Camizestrant 10 mg/kg daily was profiled in 28 PDX models, and head-to-head with fulvestrant at 5 mg/weekly in 25 ER+ PDX models derived from primary or metastatic tumors, naïve or exposed to ET and/or CDK4/6i, and with various ESR1m status (Fig. 3A and B).